Cilo Cybin Pharmaceutical (Cilo Cybin) has announced that the ALPS Global Holding Berhad (ALPS) Group of companies, a fully integrated biotechnology research, medical and wellness company operating in Kuala Lumpur, Malaysia, has acquired a 10% equity shareholding in Cilo Cybin.
The acquisition is aimed at supporting Cilo Cybin in its upcoming IPO efforts later this year.
ALPS has agreed to underwrite the IPO for Cilo Cybin to ensure a listing on the JSE.
Gabriel Theron, Founder and CEO of Cilo Cybin, says his Board is delighted to have ALPS on board as a partner.
“Our decision to delay the SPAC listing on the JSE in November last year proved to be both prudent and fortunate. The additional time allowed Cilo Cybin to secure a significant investment that not only paves the way to a listing on the JSE but also provides a gateway for Cilo Cybin and ALPS to jointly enter, investigate and secure new markets with a distinctively combined and strategically positioned service offering.”
Cilo Cybin combines Biotech and Pharmaceutical methodologies to deliver a holistic and individualised solution that enhances health, performance and longevity through the use of technologies, apps, devices, supplementation and medication.
Dr THAM Seng Kong, Group CEO and Group Chief Research Scientist of ALPS, said he was impressed by similarities in vision between the two companies and the many potential synergies that could benefit them both.
Theron refers to Dr THAM as the main driver leading the ALPS Group to greater heights towards recognition as a global biotechnology company.
“Today, ALPS has evolved into a fully integrated platform consisting of biotechnology research, medical and wellness establishments dealing with Predictive, Precision and Preventive Health Management expertise. ALPS is currently one of the most progressive Biomarker Precision Diagnostic Lab with full instrument Whole Genome Sequencing and cGMP stem cell cultivation in the ASEAN region, with a business focus on molecular cells as therapeutic entities.”
Headquartered in the heart of Kuala Lumpur’s Central Business District, ALPS’ core centres comprise ALPS Medical Centre, ALPS Wellness & Anti-Aging Centre (Aesthetic, Wellness and Anti-Aging Procedures), MyGenome Molecular Institute (Whole Genome Sequencing dealing with DNA and RNA expertise) and Celestialab (Cultivation of Cellular Products) – all engineered and designed to revitalize the individual’s health and well-being through the Precision & Preventive Ethos.
ALPS is also working cohesively with certain Universities in collaboration to set up a National Human Genes Bank, the first in Southeast Asia. There will also be Stem cell initiatives, through our expertise, to make available IPS Cells for pancreatic Beta-cell to treat Diabetes Mellitus I, Neuron cells for Alzheimer’s Disease and Parkinson’s Disease, cardiomyocytes for Heart valves etc. ALPS aim is to apply Whole Genome Sequencing and mRNA expressed gene profiling in future diagnostic testing and creation of personalized medicine. ALPS will soon be able to produce and cultivate autologous stem cells at our own premises.
ALPS will also be pivotal in the establishment of an international Research and Development Hub of renowned scientists and institutions involved in stem cell related research to use cellular therapy as therapeutic entities.
